Literature DB >> 7198650

Total and free estrogens and androgens in postmenopausal women with hip fractures.

B J Davidson, R K Ross, A Paganini-Hill, G D Hammond, P K Siiteri, H L Judd.   

Abstract

Hip fracture constitutes the most serious complication of postmenopausal osteoporosis. To examine the possible role of circulating estrogen or androgen levels in the development of this type of fracture, 25 patients with hip fractures after minimal trauma were compared to an equal number of controls, matched for age and years since menopause. All were from a retirement community, had intact ovaries, and had not taken estrogen replacement for longer than 3 months during their entire lifetime. Hip fracture patients were found to have a significantly lower (P = 0.031) mean (+/-SE) percent ideal weight (89.4 +/- 2.9%) than controls (100.0 +/- 2.5%). Sex hormone-binding globulin levels were significantly higher (P = 0.004) in patients (6.7 +/- 0.4 X 10-8 M) than in controls (4.9 +/- 0.3 X 10-8 M), resulting in lower concentrations of biologically available estradiol and testosterone. In a subgroup of 12 patients and controls matched for percent ideal weight, differences in sex hormone binding globulin and free testosterone and estradiol levels were no longer statistically significant; however, the difference in the percentage of free testosterone persisted. These data suggest that endogenous sex steroids in their unbound form may play a role in the pathogenesis of postmenopausal hip fractures. The differences in free hormone levels appeared to be influenced by the differences in mean body size of the 2 groups. This factor is known to have an important negative effect on the concentration of sex hormone-binding globulin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7198650     DOI: 10.1210/jcem-54-1-115

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Endogenous sex hormones and bone mineral density among community-based postmenopausal women.

Authors:  S Murphy; K T Khaw; M J Sneyd; J E Compston
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

2.  Androgens regulate bone resorption activity of isolated osteoclasts in vitro.

Authors:  L Pederson; M Kremer; J Judd; D Pascoe; T C Spelsberg; B L Riggs; M J Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Bone mineral density in Addison's disease.

Authors:  J P Devogelaer; J Crabbé; C Nagant de Deuxchaisnes
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

4.  Postoophorectomy bone loss is associated with reduced bone Gla protein serum levels: a possible effect of osteoblastic insufficiency.

Authors:  C E Fiore; E Falcidia; R Foti; S Caschetto; D R Grimaldi
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

Review 5.  Androgens and bone.

Authors:  D Vanderschueren; R Bouillon
Journal:  Calcif Tissue Int       Date:  1995-05       Impact factor: 4.333

6.  Sex steroids, bone turnover and bone mineral density in pre-, peri-, and postmenopausal women.

Authors:  T Akatsu
Journal:  Environ Health Prev Med       Date:  1998-10       Impact factor: 3.674

Review 7.  Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.

Authors:  P Geusens
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

8.  Age-related pathology and biosenescent markers in captive rhesus macaques.

Authors:  H Uno
Journal:  Age (Omaha)       Date:  1997-01

9.  Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.

Authors:  H Rico; A Charro; I Depablos; E Bordiu; E R Hernandez; D Espinos
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

Review 10.  The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.

Authors:  Rhonda Orr; Maria Fiatarone Singh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.